What question did this study set out to answer?

To correct errors regarding enzyme activities and improve clarity on the effectiveness of asparaginase.

April 27, 2026Open Access

Correction: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion

Key Points

To correct errors regarding enzyme activities and improve clarity on the effectiveness of asparaginase.
Corrected enzyme names to proper formatting; highlighted errors in Table 1 and figure captions.
Ensured enzyme names were italicized except for the letter 'A'.
Reviewed data including mouse half-life and catalytic efficiencies in context of leukemia models.
The corrected enzyme activity data now accurately reflects kcat and Km values pertinent to asparaginase's efficacy.
The clarification of the mouse model study design provides critical insights for the effects of EBD-300 treatment.
Statistical methods applied, including t-tests, ensure validity of findings related to leukemic growth suppression.

Abstract

Wrong content There were several errors in Table 1 as originally published. The unit reported next to kcat was incorrect and should be s⁻¹. In addition, the Michaelis-Menten constant was incorrectly written as km and should be corrected to Km, and the unit µM should be corrected to mM. For Km: the "m" is NOT subscript; Km correct, Km incorrectThe reference labels in column 1 were also incorrect: ErAref1 (10), EcAref2 (10), gpAref2 (11), and hAref2 (11) should be corrected to ErA (10), EcA (10), GpA (11), and hA (11). Furthermore, gpA should be capitalized as GpA. Lastly, in the Enzyme column, the enzyme names should be italicized (ErA, EcA, GpA, hA).The original version of this article has been updated.Mouse half-life Enzyme kcat (s -1 ) Km (µM) kcat (s The table summarizes the catalytic efficiency kcat and Michaelis-Menten constant Km for asparaginase and glutaminase activities of each L-asparaginase. Additionally, the in vivo mouse half-life is included for each enzyme.There was a mistake in the caption of Figure 1 as published. The caption stated is:EBD-300 is human-like with very high sequence identity to the human homolog and has the required kinetic properties for achieving sustained asparagine depletion without perturbing glutamine. EBD-300 is highly human-like in protein sequence compared to the asparaginase domain from the guinea pig homolog truncated at residue 369 (GpA369) but especially compared to the clinical bacterial asparaginases from E. coli (EcA) and Erwinia (ErA) (A) surface representations of the tetramers where each protomer in the tetramer is shown in a different color (gray, green, blue or orange) and residues not identical to the human homolog are denoted in red. (B) Pie charts displaying % identity compared to the human enzyme where non-human is shown in red and identity to human is show in blue. Please delete the first sentence in the figure 1 legend as shown below and add in word "protein sequence" as shown in the corrected caption belowThe corrected caption of Figure 1 should be:EBD-300 is highly human-like in protein sequence compared to the asparaginase domain from the guinea pig homolog truncated at residue 369 (GpA369) but especially compared to the clinical bacterial asparaginases from E. coli (EcA) and Erwinia (ErA) (A) surface representations of the tetramers where each protomer in the tetramer is shown in a different color (gray, green, blue or orange) and residues not identical to the human homolog are denoted in red. (B) Pie charts displaying % identity compared to the human enzyme where non-human is shown in red and identity to human is show in blue.There was a mistake in the caption of Figure 4 as published. The caption stated is:EBD-300 monotherapy suppressed leukemic growth in a del7q AML model. Human AML cells with cytogenetics were implanted in NOG mice (n = 4) and after confirming engraftment were randomly assigned to a vehicle control group and an EBD-300 group, which was dosed at 750 IU/kg Mondays and Wednesdays and 1,500 IU/kg on Fridays for a total study duration of 28 days. On Day 28 mice were sacrificed, and bone marrow (A) and blood (B) were analyzed for the presence of hCD45. The animals experienced an initial weight loss 10-15% which then stabilized for the duration of the study (C).Statistical significance was determined using Student t-test (Prism 9.1.2). The error bars shown represent the standard error of mean (SEM).The corrected caption of Figure 4 should be:EBD-300 monotherapy suppressed leukemic growth in a del7q AML model. Human AML cells (Champions Oncology model CTG-2456) with cytogenetics 46, XX, del(7)(q22q36) 15 were implanted in NOG mice (n=10) and after confirming engraftment were randomly assigned to a vehicle control group (n=10) and an EBD-300 group (n=10), which was dosed at 750 IU/kg Mondays and Wednesdays and 1,500 IU/kg on Fridays for a total study duration of 28 days. On Day 28 mice were sacrificed, and bone marrow (A) and blood (B) were analyzed for the presence of hCD45. The animals experienced an initial weight loss 10-15% which then stabilized for the duration of the study (C). Statistical significance was determined using Student t-test (Prism 9.1.2). The error bars shown represent the standard error of mean (SEM).Adding/removing text Throughout the manuscript, the enzyme names EcA, ErA, GpA, and hA were not formatted correctly. Please ensure that the enzyme names are written in italics except for the letter "A." The correct formatting should be: EcA, ErA, GpA, and hA.Please search the entire article for these enzyme names and apply this formatting consistently, ensuring that only the first letters (Ec, Er, Gp, and h) are italicized, while the letter A remains in regular font.

Bookmark

View Full Paper